Precise Health develops personalised bacteriophage technology to replace broad-spectrum antibiotics. The start-up has joined the Biopôle Investment Programme, which offers non-dilutive funding of up to CHF 90,000.
- Announced on
- Round
- Grant
- Amount
- Amount not disclosed
- Location
- canton of Valais
- Sector
- Biotech & life sciences
Investors
- Biopôle SA lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic